Reata Pharmaceuticals Top Management

RETADelisted Stock  USD 109.67  3.31  2.93%   
Reata Pharmaceuticals employs about 321 people. The company is managed by 10 executives with a total tenure of roughly 21 years, averaging almost 2.0 years of service per executive, having 32.1 employees per reported executive. Analysis of Reata Pharmaceuticals' management performance can provide insight into the company performance.
Warren Huff  Chairman
Chairman of the Board and Presidentident, CEO
Michael Wortley  President
Vice President Chief Legal Officer
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Reata Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.3766) % which means that it has lost $0.3766 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1239) %, meaning that it created substantial loss on money invested by shareholders. Reata Pharmaceuticals' management efficiency ratios could be used to measure how well Reata Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Reata Pharmaceuticals Workforce Comparison

Reata Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 5,899. Reata Pharmaceuticals holds roughly 321 in number of employees claiming about 5% of equities under Health Care industry.

Reata Pharmaceuticals Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Reata Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Reata Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Reata Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Reata Pharmaceuticals Notable Stakeholders

A Reata Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Reata Pharmaceuticals often face trade-offs trying to please all of them. Reata Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Reata Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Warren HuffChairman of the Board and Presidentident, CEOProfile
Michael WortleyVice President Chief Legal OfficerProfile
Christian WigleyVP OfficerProfile
Bhaskar AnandVP OfficerProfile
Dawn BirChief Commercial OfficerProfile
Colin MDEx OfficerProfile
Manmeet SoniCFO COOProfile
Elaine CastellanosConsultantProfile
Steve HarmanVP OfficerProfile
Dakota GallivanVP OfficerProfile

About Reata Pharmaceuticals Management Performance

The success or failure of an entity such as Reata Pharmaceuticals often depends on how effective the management is. Reata Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Reata management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Reata management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. Reata Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 346 people.
Please note, the presentation of Reata Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Reata Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Reata Pharmaceuticals' management manipulating its earnings.

Reata Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Reata Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Reata Pharmaceuticals within its industry.

Reata Pharmaceuticals Manpower Efficiency

Return on Reata Pharmaceuticals Manpower

Revenue Per Employee6.9K
Revenue Per Executive221.6K
Net Loss Per Employee971.7K
Net Loss Per Executive31.2M
Working Capital Per Employee1.1M
Working Capital Per Executive33.9M
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Other Consideration for investing in Reata Stock

If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios